Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
987.12B
Market cap987.12B
Price-Earnings ratio
50.82
Price-Earnings ratio50.82
Dividend yield
0.58%
Dividend yield0.58%
Average volume
3.26M
Average volume3.26M
High today
$1,029.93
High today$1,029.93
Low today
$1,003.50
Low today$1,003.50
Open price
$1,011.00
Open price$1,011.00
Volume
3.28M
Volume3.28M
52 Week high
$1,111.99
52 Week high$1,111.99
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $1,029.44, with a market capitalization of 987.12B. The stock trades at a price-to-earnings (P/E) ratio of 50.82 and offers a dividend yield of 58.4%.

As of 2025-12-15, Eli Lilly(LLY) stock has fluctuated between $1,003.50 and $1,029.93. The current price stands at $1,029.44, placing the stock +2.6% above today's low and -0.0% off the high.

Eli Lilly(LLY) shares are trading with a volume of 3.28M, against a daily average of 3.26M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.

LLY News

The Motley Fool 38m
Eli Lilly Just Delivered Fantastic News to Investors

Eli Lilly shares have climbed in the double digits this year. Generally, investors turn to pharmaceutical stocks to add an element of safety to their portfolio...

Eli Lilly Just Delivered Fantastic News to Investors
TipRanks 10h
Eli Lilly’s Mounjaro recommended for extended use by EMA

The European Medicines Agency’s, EMA, committee recommended a change to extend the use of Eli Lilly’s (LLY) Mounjaro for the treatment of type 2 diabetes, that...

Investor's Business Daily 15h
Tesla Model Y Seen Driving Without Safety Monitor In Austin

Dow Jones Futures Loom For Divided Market; Tesla, Eli Lilly In Buy Areas 12/12/2025 Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs la...

Tesla Model Y Seen Driving Without Safety Monitor In Austin

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
22.6%
Sell
3.2%

More LLY News

TipRanks 17h
Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund l...

TipRanks 17h
Eli Lilly’s Orforglipron Study: A Potential Game-Changer for PAD Treatment

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund l...

Nasdaq 2d
My Top 3 Healthcare Stocks to Buy in 2026

Key Points With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly r...

My Top 3 Healthcare Stocks to Buy in 2026
Simply Wall St 2d
Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far?

Wondering if Eli Lilly is still worth buying after its monster run, or if the upside has already been priced in? You are not alone, and that is exactly what thi...

Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far?
Benzinga 3d
New Eli Lilly Results Suggest Major Delay To Chemotherapy For Breast Cancer Patients

Eli Lilly and Co. (NYSE:LLY) on Friday shared updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for previously treated breast cancer pat...

Benzinga 3d
What's Going On With Eli Lilly Stock Friday? - Eli Lilly - Benzinga

...

What's Going On With Eli Lilly Stock Friday? - Eli Lilly - Benzinga
TipRanks 3d
Eli Lilly announces updated results from Phase 3 EMBER-3 study of Inluriyo

Eli Lilly (LLY) and Company announced updated results from the Phase 3 EMBER-3 study of Inluriyo, an oral estrogen receptor antagonist, in patients with estroge...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.